Abstract
AbstractHuman glucose transporters (GLUTs) are responsible for cellular uptake of hexoses. Elevated expression of GLUTs, particularly GLUT1 and GLUT3, is required to fuel the hyperproliferation of cancer cells, making GLUT inhibitors potential anticancer therapeutics. Meanwhile, GLUT inhibitor-conjugated insulin is being explored to mitigate the hypoglycemia side effect of insulin therapy in type 1 diabetes. Reasoning that exofacial inhibitors of GLUT1/3 may be favored for therapeutic applications, we report here the engineering of a GLUT3 variant, designated GLUT3exo, that can be probed for screening and validating exofacial inhibitors. We identify an exofacial GLUT3 inhibitor SA47 and elucidate its mode of action by a 2.3 Å resolution crystal structure of SA47-bound GLUT3. Our studies serve as a framework for the discovery of GLUTs exofacial inhibitors for therapeutic development.
Funder
National Natural Science Foundation of China
Beijing Nova Program
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference46 articles.
1. Mueckler, M. & Thorens, B. The SLC2 (GLUT) family of membrane transporters. Mol. Asp. Med. 34, 121–138 (2013).
2. Manolescu, A. R., Witkowska, K., Kinnaird, A., Cessford, T. & Cheeseman, C. Facilitated hexose transporters: new perspectives on form and function. Physiol. (Bethesda) 22, 234–240 (2007).
3. Lehninger, A. L., Nelson, D. L. & Cox, M. M. Lehninger Principles of Biochemistry 5th edn (W.H. Freeman, 2008).
4. Pascual, J. M. et al. GLUT1 deficiency and other glucose transporter diseases. Eur. J. Endocrinol. 150, 627–633 (2004).
5. Santer, R. et al. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat. Genet 17, 324–326 (1997).
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献